Tailored Management of Advanced Esophageal Squamous Cell Carcinoma — Balancing Efficacy and Toxicity with a “Hold Chemotherapy and Keep Immunotherapy” Strategy: A Case Report
Esophageal squamous cell carcinoma (ESCC) is an aggressive malignancy with a poor prognosis in advanced stages. Pivotal trials including ATTRACTION-3, CheckMate 648, and CheckMate 577 have demonstrated that immunotherapy with nivolumab significantly improved survival and maintained disease control....
Saved in:
| Main Authors: | Yu-Chieh Lin, Jeng-Shiun Du, Chun-Chieh Wu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-04-01
|
| Series: | Journal of Cancer Research and Practice |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/ejcrp.eJCRP-D-25-00007 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Nimotuzumab plus chemotherapy and immunotherapy as first-line/neoadjuvant therapy for advanced esophageal squamous cell carcinoma
by: Qi Wang, et al.
Published: (2025-07-01) -
Research Status and Progress on Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma in Hebei Province
by: Xiaoyang DUAN, et al.
Published: (2025-02-01) -
Immunotherapy in advanced esophageal squamous cell cancer: earlier or later?
by: Shuang Wei, et al.
Published: (2025-07-01) -
Chemo-immunotherapy sequential with radiotherapy in advanced or metastatic esophageal squamous cell carcinoma
by: Xiang Han, et al.
Published: (2025-12-01) -
The efficacy and safety of adjuvant immunotherapy after neoadjuvant immunotherapy combined with chemotherapy in locally advanced resectable esophageal squamous cell carcinoma: a real−world study
by: Xue Wu, et al.
Published: (2025-05-01)